These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
7. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756 [TBL] [Abstract][Full Text] [Related]
9. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
11. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
12. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
13. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. Hohman TJ; Bell SP; Jefferson AL; JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166 [TBL] [Abstract][Full Text] [Related]
14. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses. Nation DA; Ho JK; Dutt S; Han SD; Lai MHC; J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
16. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. Handoko M; Grant M; Kuskowski M; Zahs KR; Wallin A; Blennow K; Ashe KH JAMA Neurol; 2013 May; 70(5):594-9. PubMed ID: 23479202 [TBL] [Abstract][Full Text] [Related]